10.6  0.02 (0.19%)		05-06 16:00
Open: 10.6 High: 10.6009 Volume: 14,132		Pre. Close: 10.58 Low: 10.57 Market Cap: 357(M)

Short term
Mid term
Targets	6-month :	12.38	1-year :	14.46
Resists	First :	10.6	Second :	12.38
Pivot price	10.55
Supports	First :	10.53	Second :	10.48
MAs	MA(5) :	10.56	MA(20) :	10.54
	MA(100) :	10.45	MA(250) :	10.33
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	91.2	D(3) :	86.2
RSI	RSI(14): 71.5
52-week	High :	10.6	Low :	10.09

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DMAA ] has closed above the upper band by 7.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	10.61 - 10.66	10.66 - 10.7
Low:	10.46 - 10.51	10.51 - 10.56
Close:	10.52 - 10.6	10.6 - 10.67

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Tue, 05 May 2026
DMAA (NASDAQ: DMAA) sets $1.0B PAGC merger with 90/10 ownership split - Stock Titan

Sat, 02 May 2026
DMAA Corp Extends Business Combination Deadline to April 29, 2027 Following Shareholder Approval – SEC 8-K Filing Update - Minichart

Fri, 01 May 2026
Drugs Made in America (NASDAQ: DMAA) holders redeem $99M from SPAC trust - Stock Titan

Tue, 28 Apr 2026
Drugs Made in America (NASDAQ: DMAA) details new CEO pay deal - Stock Titan

Thu, 23 Apr 2026
DMAA | Drugs Made In America Insider Trading - Quiver Quantitative

Wed, 15 Apr 2026
Drugs Made In America (NASDAQ: DMAA) details SPAC cash, LOI and risks - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	34 (M)
Shares Float	27 (M)
Held by Insiders	26.6 (%)
Held by Institutions	70.9 (%)
Shares Short	1,470 (K)
Shares Short P.Month	25 (K)

EPS	0.18
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.22
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-1.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	55.78
PEG Ratio	0
Price to Book value	-48.19
Price to Sales	0
Price to Cash Flow	-662.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.